邮箱：liuchang@zzu.edu.cn
地址：郑州大学天健生物医学实验室2号楼808室
个人简介
2010年起先后在河南大学、复旦大学完成材料化学学士、无机化学硕士和药物化学博士培养；2021年起先后在复旦大学和同济大学开展药剂学与临床医学博士后研究，形成了药物化学、药剂学及临床医学多学科交叉融合的研究背景。2025年至今任郑州大学医学前沿交叉学院初聘副教授，硕士生导师。
主要研究方向
有机小分子染料在荧光成像与光动力治疗中的应用
主持或参加科研项目情况
(1) 青年基金，82504750，2026.01-2028.12，30万，主持
(2) 国家资助博士后研究人员计划（C），GZC20241235，2023.07-2025.07，24万，主持
代表性成果
(1) Chang Liu, Runtong Zhang, Yi Lu, Zongguang Tai, Quangang Zhu, Zhongjian Chen*, Wei Wu*. ACQ-FRET dual-functional near-infrared fluorescent probes for the bioimaging of nanocarriers. Asian Journal of Pharmaceutical Sciences, 2026, 21(2), 101140.
(2) Chang Liu, Yifan Cai, Zichen Zhang, Yi Lu, Quangang Zhu, Haisheng He*, Zhongjian Chen*, Weili Zhao*, Wei Wu*. Julolidinyl Aza-BODIPYs as NIR-II fluorophores for the bioimaging of nanocarriers. Acta Pharmaceutica Sinica B, 2024, 14 (7), 3155.
(3) Chang Liu, Chuan Liu, Xin Ji, Weili Zhao*, Xiaochun Dong*. Synthesis and photodynamic activities of pyridine- or pyridinium- substituted Aza-BODIPY photosensitizers. Journal of Medicinal Chemistry, 2024, 67 (17), 15908.
(4) Chang Liu, Xin Ji, Zhiliang Yu, Shaohui Zhang, Rong Zhang, Weili Zhao, Xiaochun Dong*. Discovery of subcellular-targeted Aza-BODIPY photosensitizers for efficient photodynamic antitumor therapy. Journal of Medicinal Chemistry, 2023, 66 (11), 7205.
(5) Chang Liu, Yue Jin, Xin Ji, Weili Zhao*, Xiaochun Dong*. Access to pyridinyl or pyridinium Aza-BODIPYs with tunable near-infrared fluorescence through ICT from 4-pyridinyl pyrroles. Chemistry-A European Journal, 2022, 28, e202201503.
(6) Yanlei Zhan, Zhichao Chang, Chang Liu, Ziyu Zhang, Runtong Zhan, Yi Lu , Jianping Qi , Wei Wu*, Haisheng He*. Tracking in vivo lipolysis of lipid nanocarriers using NIR-II polarity-sensitive fluorescent probes. Small Methods, 2025, 2402249.
(7) Chang Liu, Yanyang Nan, Zhifeng Xia, Kedan Gu, Cheng Chen, Xiaochun Dong, Dianwen Ju*, Weili Zhao*. Discovery of novel hydroxyamidine derivatives as indoleamine 2,3-dioxygenase 1 inhibitors with in vivo anti-tumor efficacy. Bioorganic & Medicinal Chemistry Letters, 2020, 30 (8), 127038.
